ArticleFrontiers in oncology2024

A good response to furmonertinib fourth-line treatment of an advanced lung adenocarcinoma patient with EGFR exon20in and PIK3CA mutation: a case report and literature review.

Kai Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.